SINGAPORE - GLAXOSMITHKLINE plans to start producing vaccines from 2011 in Singapore to fight pneumonia-causing bacteria, which kills more than 1 million children each year around the world.
The world's second biggest drugmaker opened a S$600 million plant in the city-state on Tuesday, its second global site to manufacture the pneumococcal conjugate vaccine after Belgium.
GSK would take up to two years to test run the plant before commercial production starts, CEO Andrew Witty said.
